Sustained efficacy and long-term safety of oxcarbazepine: One-year open-label extension of a study in refractory partial epilepsyBEYDOUN, Ahmad; SACHDEO, Rajesh C; KUTLUAY, Ekrem et al.Epilepsia (Copenhagen). 2003, Vol 44, Num 9, pp 1160-1165, issn 0013-9580, 6 p.Article

A double-blind, randomized, placebo-controlled trial of oxcarbazepine in the treatment of bipolar disorder in children and adolescentsDINEEN WAGNER, Karen; KOWATCH, Robert A; LINDEN, David et al.The American journal of psychiatry. 2006, Vol 163, Num 7, pp 1179-1186, issn 0002-953X, 8 p.Article

Extended-Release Dexmethylphenidate 30 mg/d Versus 20 mg/d: Duration of Attention, Behavior, and Performance Benefits in Children With Attention-Deficit/Hyperactivity DisorderSILVA, Raul R; BRAMS, Matthew; MCCAGUE, Kevin et al.Clinical neuropharmacology. 2013, Vol 36, Num 4, pp 117-121, issn 0362-5664, 5 p.Article

A Randomized, Double-Blind Study of 30 Versus 20 mg Dexmethylphenidate Extended-Release in Children With Attention-Deficit/Hyperactivity Disorder: Late-Day Symptom ControlBRAMS, Matthew; TURNBOW, John; PESTREICH, Linda et al.Journal of clinical psychopharmacology. 2012, Vol 32, Num 5, pp 637-644, issn 0271-0749, 8 p.Article

A Randomized, Double-Blind, Crossover Study of Once-Daily Dexmethylphenidate in Children with Attention-Deficit Hyperactivity Disorder : Rapid Onset of EffectBRAMS, Matthew; MUNIZ, Rafael; CHILDRESS, Ann et al.CNS drugs. 2008, Vol 22, Num 8, pp 693-704, issn 1172-7047, 12 p.Article